RANI
Rani Therapeutics Holdings, Inc. NASDAQ Listed Jul 30, 2021$0.79
Pre-mkt
$0.81
+2.27%
Mkt Cap $51.7M
52w Low $0.44
10.3% of range
52w High $3.87
50d MA $0.78
200d MA $1.20
P/E (TTM)
—
EV/EBITDA
—
P/B
1.3x
Debt/Equity
0.1x
ROE
-124.0%
P/FCF
-2.8x
RSI (14)
60.60
ATR (14)
$0.08
Beta
0.66
50d MA
$0.78
200d MA
$1.20
Avg Volume
926.6K
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
CIK (SEC)
Phone
408 457 3700
2051 Ringwood Avenue · San Jose, CA 95131 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | AMC | -0.06 | -0.04 | +33.3% | 1.08 | -1.9% | -10.0% | -9.0% | +23.2% | -1.8% | +0.0% | — |
| Mar 26, 2026 | AMC | -0.03 | -0.07 | -133.3% | 1.08 | -2.8% | -24.9% | -5.9% | -3.7% | +9.6% | +4.3% | — |
| Nov 6, 2025 | AMC | -0.09 | -0.12 | -33.3% | 2.27 | -14.1% | -11.0% | -7.9% | +4.3% | +9.3% | -9.0% | — |
| Aug 7, 2025 | AMC | -0.19 | -0.18 | +5.3% | 0.53 | -2.4% | -0.9% | -5.3% | +6.2% | -0.6% | +5.5% | — |
| May 13, 2025 | AMC | -0.22 | -0.22 | +0.0% | 0.48 | +16.0% | +15.6% | +2.5% | +12.2% | +9.3% | +7.0% | — |
| Mar 31, 2025 | AMC | -0.24 | -0.27 | -12.5% | 1.26 | -0.8% | -2.4% | +13.0% | -6.5% | -6.9% | -7.4% | — |
| Nov 14, 2024 | AMC | -0.22 | -0.24 | -9.1% | 2.35 | +0.9% | -3.4% | -9.7% | +0.5% | -0.5% | -0.5% | — |
| Aug 6, 2024 | AMC | -0.29 | -0.26 | +10.3% | 2.50 | +1.2% | -2.8% | -0.8% | -6.2% | +4.9% | +13.9% | — |
| May 6, 2024 | AMC | -0.23 | -0.29 | -26.1% | 7.56 | -0.1% | -1.3% | -4.2% | -5.2% | -6.9% | -3.2% | — |
| Mar 20, 2024 | AMC | -0.31 | -0.27 | +12.9% | 3.57 | +0.8% | +0.8% | -9.4% | -0.6% | -1.9% | -4.7% | — |
| Nov 8, 2023 | AMC | -0.47 | -0.36 | +23.4% | 1.98 | -2.0% | -3.0% | +3.1% | -1.5% | +1.3% | +0.8% | — |
| Aug 11, 2023 | AMC | -0.40 | -0.37 | +7.5% | 4.20 | +2.4% | +4.5% | -2.5% | -2.8% | -3.6% | +2.2% | — |
| May 10, 2023 | AMC | -0.47 | -0.33 | +29.8% | 4.30 | +0.2% | -8.8% | +2.6% | +2.0% | -0.5% | +12.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $0.73 | $0.74 | +0.8% | +9.6% | +4.3% | -1.2% | -1.5% | +1.7% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.08 | $1.05 | -2.8% | -24.9% | -5.9% | -3.7% | +9.6% | +4.3% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.39 | $1.41 | +1.4% | +0.7% | +6.4% | -4.7% | -1.4% | -0.7% |
| Oct 20 | Maxim Group | Maintains | Buy → Buy | — | $1.64 | $2.10 | +28.0% | +37.2% | +26.7% | -15.1% | -13.6% | -12.9% |
| May 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $0.57 | $0.57 | -0.1% | +12.2% | +9.3% | +7.0% | -5.5% | -8.5% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.39 | $1.30 | -6.5% | -6.5% | -6.9% | -7.4% | -5.4% | +18.9% |
| Feb 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.47 | $1.45 | -1.4% | +4.8% | -2.6% | +2.0% | -3.9% | -2.7% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.65 | $1.60 | -3.0% | -7.9% | -6.6% | -0.7% | +19.9% | +8.9% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.05 | $2.03 | -1.0% | +0.5% | -0.5% | -0.5% | +2.0% | +0.0% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.63 | $2.64 | +0.4% | +1.9% | -4.1% | -7.4% | +5.9% | -5.2% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.68 | $2.62 | -2.2% | +4.1% | +2.5% | +0.3% | +1.4% | +5.5% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.11 | $4.11 | +0.0% | -9.0% | +4.0% | +1.3% | -3.6% | +0.5% |
| May 9 | BTIG | Maintains | Buy → Buy | — | $7.15 | $7.23 | +1.1% | -5.2% | -6.9% | -3.2% | -5.4% | -4.3% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.56 | $7.55 | -0.1% | -1.3% | -4.2% | -5.2% | -6.9% | -3.2% |
| Mar 27 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.18 | $3.03 | -4.7% | -4.7% | +2.6% | +0.6% | +0.3% | +5.4% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.26 | $3.22 | -1.2% | -0.6% | -1.9% | -4.7% | +2.6% | +0.6% |
| Feb 6 | Wedbush | Maintains | Outperform → Outperform | — | $3.69 | $3.80 | +3.0% | +1.9% | +0.8% | +0.3% | -0.3% | -5.8% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.98 | $1.94 | -2.0% | -3.0% | +3.1% | -1.5% | +1.3% | +0.8% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.95 | $2.95 | +0.0% | -6.1% | +6.9% | -6.1% | -0.7% | +6.9% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.75 | $3.75 | +0.0% | -0.8% | -7.3% | -10.7% | -1.0% | -4.3% |
| Aug 21 | BofA Securities | Maintains | Buy → Buy | — | $4.10 | $4.04 | -1.5% | -3.7% | -3.8% | +1.1% | +3.1% | -3.8% |
| Aug 17 | Wedbush | Maintains | Outperform → Outperform | — | $4.16 | $4.25 | +2.2% | -3.6% | +2.2% | -3.7% | -3.8% | +1.1% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.20 | $4.30 | +2.4% | +4.5% | -2.5% | -2.8% | -3.6% | +2.2% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.63 | $4.64 | +0.2% | +6.5% | -3.0% | +3.6% | +1.8% | -5.8% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.30 | $4.31 | +0.2% | -8.8% | +2.6% | +2.0% | -0.5% | +12.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 21, 2026 | IMRAN MIR A | — | Buy | 36,000 | $0.69 | $25K | 2,119,334 | -4.39% | -2.80% |
| Jul 17, 2026 | Imran Talat | Chief Executive Officer | Buy | 35,000 | $0.72 | $25K | 469,736 | +29.77% | +1.14% |
| Mar 27, 2026 | Javadi Alireza | Chief Technical Officer | Sell | 386 | $0.78 | $301 | 9,689 | +29.77% | +1.14% |
| Dec 27, 2024 | Imran Talat | Chief Executive Officer | Sell | 8,014 | $1.41 | $11K | 486,737 | +29.77% | +1.14% |
8-K
Rani Therapeutics Holdings, Inc. -- 8-K Filing
Aug 4
8-K · 5.02
!!! Very High
Rani Therapeutics Holdings, Inc. -- 8-K 5.02: Executive Change
Rani Therapeutics appointed Maestas as Chief Financial Officer effective June 29, 2026, replacing the previous CFO and signaling potential strategic shifts in financial management and investor communications.
Jun 30
8-K
Rani Therapeutics Holdings, Inc. -- 8-K Filing
May 29
8-K
Rani Therapeutics Holdings, Inc. -- 8-K Filing
May 27
8-K
Unknown — 8-K Filing
Rani Therapeutics secured a transformative $1.085 billion partnership with Chugai Pharmaceutical, significantly de-risking its pipeline and providing substantial funding for clinical development and commercialization efforts.
Mar 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Samsara Biocapital, Llc | 8,500,000 | $11M | New | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 4,622,567 | $3M | New | Mar 2026 |
| 3 | Longaeva Partners L.p. | 2,329,459 | $2M | Added | Mar 2026 |
| 4 | Nan Fung Group Holdings Ltd | 493,584 | $363K | — | Mar 2026 |
| 5 | Millennium Management | 405,669 | $298K | Added | Mar 2026 |
| 6 | Kestra Private Wealth Services, Llc | 265,159 | $195K | Added | Mar 2026 |
| 7 | Ubs Group Ag | 227,223 | $167K | Added | Mar 2026 |
| 8 | Susquehanna International Group, Llp | 188,222 | $138K | Added | Mar 2026 |
| 9 | Northern Trust Corp | 170,471 | $125K | — | Mar 2026 |
| 10 | Cygnus Capital Advisors, Llc | 115,649 | $85K | New | Mar 2026 |
| 11 | Morgan Stanley | 57,354 | $77K | Added | Dec 2025 |
| 12 | Farallon Capital Management Llc | 78,000 | $57K | New | Mar 2026 |
| 13 | King Luther Capital Management Corp | 58,000 | $43K | — | Mar 2026 |
| 14 | Qube Research & Technologies Ltd | 47,508 | $35K | Reduced | Mar 2026 |
| 15 | Nine Masts Capital Ltd | 44,849 | $33K | New | Mar 2026 |
| 16 | Lafayette Investments, Inc. | 22,979 | $31K | Added | Dec 2025 |
| 17 | China Universal Asset Management Co., Ltd. | 15,894 | $21K | New | Dec 2025 |
| 18 | Ctc Alternative Strategies, Ltd. | 23,622 | $17K | New | Mar 2026 |
| 19 | Catalyst Funds Management Pty Ltd | 14,800 | $11K | New | Mar 2026 |
| 20 | Bank Of New York Mellon Corp | 13,879 | $10K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 9
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 402,413 | $551K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 203,037 | $149K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 138,177 | $131K | May 2026 |
| 4 | Fidelity Series Total Market Index Fund | 115,378 | $110K | May 2026 |
| 5 | Ultra-Small Company Market Fund | 114,500 | $84K | Mar 2026 |
| 6 | Fidelity Nasdaq Composite Index Fund | 49,504 | $68K | Feb 2026 |
| 7 | Invesco Nasdaq Biotechnology ETF | 5,458 | $7K | Feb 2026 |
| 8 | Victory Extended Market Index Fund | 5,918 | $7K | Jan 2026 |
| 9 | ProShares Ultra Nasdaq Biotechnology | 4,504 | $6K | Feb 2026 |
Valuation
Market Cap
$51.7M
Enterprise Value
$5.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.05x
P/B
1.26x
P/S
16.32x
P/FCF
-2.79x
EV/EBITDA
—
Shares Out
66.1M
Financials (TTM)
Revenue
$3.2M
Net Income
-$29.4M
EBITDA
-$33.4M
Free Cash Flow
-$18.8M
Op Cash Flow
-$18.7M
EPS Basic
$-0.45
EPS Diluted
$-0.41
EPS Forward
$-0.20
Gross Margin
94.9%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$58.6M
Total Liab.
$17.1M
Total Equity
$41.5M
Cash
$49.7M
LT Debt
$2.7M
Book Value/Sh
$0.63
Debt/Equity
0.13x
Current Ratio
4.21
Quick Ratio
4.21
Returns & Growth
ROE
-124.0%
ROA
-69.9%
ROIC
-80.6%
Rev Growth YoY
+58.9%
EPS Growth YoY
+57.1%
Price Returns
2W
-6.9%
1M
+14.3%
3M
-18.0%
6M
-35.1%
12M
+50.0%
Technicals
52W High
$3.87
52W Low
$0.44
50d MA
$0.78
200d MA
$1.20
RSI (14)
60.60
ATR (14)
$0.08
Beta
0.66
Avg Volume
927K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$15.67
High
$28.00
Low
$9.00
Median
$10.00
Data updated apr 26, 2026 9:53pm
· Source: financialmodelingprep.com